Published in Haematologica on October 01, 2007
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.07
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
The future of autologous stem cell transplantation in myeloma. Blood (2014) 0.99
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood (2015) 0.97
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood (2014) 0.89
Retrospective analysis of 264 multiple myeloma patients. Oncol Lett (2012) 0.88
Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant (2015) 0.88
Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med (2013) 0.84
Surgical therapy of skeletal complications in multiple myeloma. Int Orthop (2010) 0.83
Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma. Oncologist (2013) 0.83
Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma. Exp Hematol Oncol (2012) 0.82
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. J Hematol Oncol (2012) 0.82
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. Adv Hematol (2014) 0.81
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. PLoS One (2014) 0.79
Long-term survival in multiple myeloma: a single-center experience. Clin Exp Med (2008) 0.79
Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med (2014) 0.79
Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol (2013) 0.78
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc (2016) 0.78
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J (2014) 0.78
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma. Am J Hematol (2012) 0.78
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials. Onco Targets Ther (2015) 0.77
Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother (2013) 0.77
Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation. Biomed Res Int (2014) 0.76
Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases. Mol Clin Oncol (2015) 0.76
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Mol Ther Oncolytics (2016) 0.75
Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci (2016) 0.75
Once-Weekly 1.6 mg/m(2) Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy. Indian J Hematol Blood Transfus (2016) 0.75
Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget (2016) 0.75
Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients. Onco Targets Ther (2016) 0.75
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica (2014) 0.75
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol (2017) 0.75
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest (2007) 4.77
Analysis of optical absorption in silicon nanowire arrays for photovoltaic applications. Nano Lett (2007) 4.27
Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet (2006) 3.87
Trouble at rest: how correlation patterns and group differences become distorted after global signal regression. Brain Connect (2012) 3.73
Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry (2008) 3.22
Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature (2011) 3.18
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol (2004) 3.18
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
A selective filter for cytoplasmic transport at the axon initial segment. Cell (2009) 3.09
High-performance flat-panel solar thermoelectric generators with high thermal concentration. Nat Mater (2011) 2.96
A new method for improving functional-to-structural MRI alignment using local Pearson correlation. Neuroimage (2008) 2.94
Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry (2006) 2.90
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet (2011) 2.85
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol (2007) 2.38
Amygdala and ventrolateral prefrontal cortex function during anticipated peer evaluation in pediatric social anxiety. Arch Gen Psychiatry (2008) 2.37
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement (2013) 2.31
An analysis of the indications for cesarean section in a teaching hospital in China. Eur J Obstet Gynecol Reprod Biol (2013) 2.26
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
Design and analysis of non-inferiority mortality trials in oncology. Stat Med (2003) 2.24
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J (2006) 2.13
The host type I interferon response to viral and bacterial infections. Cell Res (2005) 2.12
Abnormal ventromedial prefrontal cortex function in children with psychopathic traits during reversal learning. Arch Gen Psychiatry (2008) 2.06
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
Cyclophilin A/Cluster of Differentiation 147 Interactions Participate in Early Brain Injury After Subarachnoid Hemorrhage in Rats. Crit Care Med (2015) 2.01
Enhanced thermoelectric figure-of-merit in nanostructured p-type silicon germanium bulk alloys. Nano Lett (2008) 1.97
SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest (2007) 1.96
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood (2002) 1.94
A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet (2011) 1.92
Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation. Am J Respir Crit Care Med (2011) 1.84
Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. Ann Thorac Surg (2005) 1.82
Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol (2010) 1.82
Modifying the DPClus algorithm for identifying protein complexes based on new topological structures. BMC Bioinformatics (2008) 1.81
Disposable circumcision suture device: clinical effect and patient satisfaction. Asian J Androl (2014) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
The Urban Resident Basic Medical Insurance: a landmark reform towards universal coverage in China. Health Econ (2009) 1.74
Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J Neurosci (2008) 1.72
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res (2011) 1.72
Adolescents, adults and rewards: comparing motivational neurocircuitry recruitment using fMRI. PLoS One (2010) 1.70
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet (2010) 1.69
Patterns of neural connectivity during an attention bias task moderate associations between early childhood temperament and internalizing symptoms in young adulthood. Biol Psychiatry (2013) 1.68
Optical absorption enhancement in silicon nanohole arrays for solar photovoltaics. Nano Lett (2010) 1.66
Tunable spin-orbit coupling and quantum phase transition in a trapped Bose-Einstein condensate. Sci Rep (2013) 1.66
Retracted Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS One (2012) 1.64
Experimental studies on anisotropic thermoelectric properties and structures of n-type Bi2Te2.7Se0.3. Nano Lett (2010) 1.63
Surface phonon polaritons mediated energy transfer between nanoscale gaps. Nano Lett (2009) 1.63
Prevalence of hypertension in china: a cross-sectional study. PLoS One (2013) 1.60
Evaluation of biocompatibility of polypyrrole in vitro and in vivo. J Biomed Mater Res A (2004) 1.59
Flavoprotein autofluorescence imaging of neuronal activation in the cerebellar cortex in vivo. J Neurophysiol (2004) 1.58
Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat Genet (2013) 1.57
A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis (2012) 1.56
High thermal conductivity of single polyethylene chains using molecular dynamics simulations. Phys Rev Lett (2008) 1.56
Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage (2010) 1.55
Coherent phonon heat conduction in superlattices. Science (2012) 1.53
Direct measurement of room-temperature nondiffusive thermal transport over micron distances in a silicon membrane. Phys Rev Lett (2013) 1.53
Incidence of functional limitation in older adults: the impact of gender, race, and chronic conditions. Arch Phys Med Rehabil (2002) 1.52
Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy (2010) 1.51
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol (2012) 1.50
Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet (2012) 1.49
Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev (2002) 1.49
Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos (2007) 1.48
Efficient light trapping in inverted nanopyramid thin crystalline silicon membranes for solar cell applications. Nano Lett (2012) 1.48
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica (2012) 1.47
Influence of simvastatin on microthrombosis in the brain after subarachnoid hemorrhage in rats: a preliminary study. Ann Clin Lab Sci (2010) 1.47
Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46
Procedural arrhythmia termination and long-term single-procedure clinical outcome in patients with non-paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2013) 1.45
Cerebellar cortical molecular layer inhibition is organized in parasagittal zones. J Neurosci (2006) 1.44
Glutamine preconditioning protects against tourniquet-induced local and distant organ injury in a rodent ischemia-reperfusion model. Acta Orthop (2007) 1.43
Right ventricular outflow pacing induces less regional wall motion abnormalities in the left ventricle compared with apical pacing. Europace (2011) 1.42
Neural response to self- and other referential praise and criticism in generalized social phobia. Arch Gen Psychiatry (2008) 1.40
Design and sample size considerations for simultaneous global drug development program. J Biopharm Stat (2012) 1.39
Medium optimization for the production of avermectin B1a by Streptomyces avermitilis 14-12A using response surface methodology. Bioresour Technol (2009) 1.37
PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res (2008) 1.37
ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol (2014) 1.37
Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One (2013) 1.33
Enhanced thermoelectric figure of merit of p-type half-Heuslers. Nano Lett (2010) 1.32
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
T cells require Foxo1 to populate the peripheral lymphoid organs. Eur J Immunol (2009) 1.27
Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer (2013) 1.27